|
Patent landscape, scope, and claims: |
Scope and patent landscape for U.S. Patent 9,908,845 (compound of Formula I/III and VHL disease and renal cell carcinoma methods)
U.S. Patent 9,908,845 claims a family of substituted fluorinated/aromatic heteroaromatic “Formula I/III/IV/V” compounds, specific enantiomeric enrichment (claim 12), three pharmaceutical composition claims (claims 15-17), and broad treatment methods for VHL disease and renal cell carcinoma (claims 18-28). The claim set is structured as: (i) generic chemical coverage via Formula I (claim 1) and narrower Formula III (claim 5) and specific structures (claims 9-14), (ii) downstream composition protection (claims 15-17), and (iii) use protection for VHL disease and renal cell carcinoma, including clear cell RCC as an explicit embodiment (claims 20-21). This architecture creates a layered infringement case against generics if they make, sell, or use any compound that falls within the Formula claims, regardless of the salt or delivery vehicle, and creates method-of-use leverage even when pharmaceutical dosage forms differ.
What does U.S. Patent 9,908,845 claim: Formula I compound scope and key limitations?
Claim 1 core coverage (Formula I)
Claim 1 covers “a compound of Formula I or a pharmaceutically acceptable salt thereof” with substituent-defined variables R1–R4 plus a specific proviso when R3 is H.
R1 (aryl/heteroaryl):
- R1 is monocyclic aryl or monocyclic heteroaryl.
- Claim 1 further restricts R1 by a selection group in the claim text (appearing as a substituted phenyl/pyridyl-like structure with variables X, R6, R7). The claim text you provided indicates:
- X is N or C R7 (so “X” can introduce a heteroatom N or a carbon substitution pattern)
- R6 is cyano, halo, alkyl or alkoxy
- R7 is hydrogen, cyano, halo, alkyl or alkoxy
- R1 may also be optionally substituted with additional cyano/halo/alkyl/alkoxy substituents.
R2 (linker/functional handle, heavily permissive):
- R2 is carboxaldehyde, carboxylic acid, ester, amido, cyano, halo, sulfonyl or alkyl.
R3 (core diversification or ring formation):
- R3 can be hydrogen, halo, cyano, alkyl, heteroalkyl, alkenyl, alkynyl, alkylamino, carboxaldehyde, carboxylic acid, ester, amido or acyl.
- Or, via the claim’s proviso construct:
- R2/R3 and atoms they are attached to form a 5- or 6-membered carbocycle with at least one sp3 hybridized carbon.
R4 (sulfur(=O) and sulfoximinyl motif):
- R4 is cyano, fluoroalkyl, alkylsulfonamide or sulfoximinyl.
- Proviso (important narrowing): when R3 is H, then R4 must be —S(═O)(═NRb)Ra, where:
- Ra is fluoroalkyl
- Rb is hydrogen or alkyl
Practical meaning for scope:
- Claim 1 is a broad substituted heteroaromatic-fluorinated scaffold claim where the most “signature” chemical constraint is the R4 sulfur motif and, depending on whether R3=H, the sulfoximine-like S(=O)(=N…) group with fluoroalkyl substituent.
- The “R2/R3 ring-forming” option increases potential scope by allowing intramolecular cyclization to a 5- or 6-membered carbocycle (with an sp3 carbon).
Claim 1 is not limited to VHL alone
Claim 1 is purely chemical (plus salt), not an indication claim. It becomes the base for composition (claim 15) and method (claim 18 for VHL).
How narrow are claims 2-4 relative to claim 1 (aryl/heteroaryl and sulfone substitutions)?
Claim 2 and 3 (R1 narrowed to phenyl or pyridyl)
- Claim 2: R1 is phenyl or pyridyl.
- Claim 3: that phenyl/pyridyl is substituted with one or more from halo, alkyl, alkoxy, cyano.
This narrows the R1 selection within claim 1 but still preserves multiple substitution patterns.
Claim 4 (specific S(O)2-NHR motif)
- Claim 4: R4 is —S(═O)2—NHR, where R is alkyl or cycloalkyl.
This is a specific alternative to the general R4 group in claim 1 and is likely to cover a subset of sulfonamide-bearing embodiments.
What does Formula III (claim 5) add versus Formula I (claim 1)?
Claim 5 core coverage (Formula III)
Claim 5 covers a compound of Formula III with variables:
- R1: monocyclic aryl or monocyclic heteroaryl.
- R4: halo, cyano, fluoroalkyl, sulfinyl, alkylsulfonamide, sulfonyl or sulfoximinyl.
- n: 1, 2, 3, or 4.
- R8: hydrogen, hydroxy, alkoxy or amino.
- R9: hydrogen, alkyl, alkenyl, alkynyl, or R8 and R9 form oxo.
- Each R10 independently: fluoro, hydroxy, alkyl, heteroalkyl.
- Proviso: when R10 is hydroxy, n is 1 or 2.
Scope impact:
- Claim 5 increases flexibility on the scaffold via n and R10 multiplicity (fluoro/hydroxy/alkyl/heteroalkyl), while constraining substitution geometry via the hydroxy-n proviso.
Claims 6-8 (substituent-specific narrowing)
- Claim 6: R8 is hydroxy or amino.
- Claim 7: R9 is hydrogen.
- Claim 8: n is 1 or 2 and R10 is fluoro.
Claim 8 is a further narrowing of the Formula III space to an “all fluoro at R10” type embodiment plus restricted n.
What do claims 9-14 cover (explicit Formula IV/V structures and a single named compound)?
Claims 9-11 (Formula IV/V and R4 selection)
- Claim 9: compound of Formula IV with R8 hydroxy or amino.
- Claim 10: compound of Formula V.
- Claim 11: Formula III variant where R4 is fluoroalkyl, sulfonyl or sulfoximinyl.
These claims serve as “bridge” points between the broad formula claims and a fully specified example.
Claim 12 (enantiomeric excess)
- Claim 12: the compound of claim 5 has enantiomeric excess ≥ about 85%.
This creates an enforcement handle: an accused infringer could argue they make a racemate or different ee. If their product falls into claim 5 but with lower ee, that could reduce claim coverage depending on how the ee language is interpreted in the full patent text (the claim as provided sets the minimum).
Claim 13 (R1 is phenyl/pyridyl with defined substitution group)
- Mirrors claim 3’s R1 narrowing, applied to claim 5.
Claim 14 (single compound identity)
- Claim 14: a compound that is (S)-3-((2,2-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (or pharmaceutically acceptable salt).
This is the strongest “pin” in the chemical claim set: it targets one stereochemically specified compound, likely the active.
Which pharmaceutical composition claims exist and what do they protect?
Claim 15-17 (composition coverage across claim bases)
- Claim 15: a pharmaceutical composition with a therapeutically effective amount of the compound/salt according to claim 1 and a pharmaceutically acceptable carrier.
- Claim 16: composition with a therapeutically effective amount of the compound/salt according to claim 5 and a pharmaceutically acceptable carrier.
- Claim 17: composition with a therapeutically effective amount of the compound/salt according to claim 14 and carrier.
Infringement consequence:
- Composition claims can reach a generic even if it uses a different dosage form strategy, as long as the claimed compound and carrier combinations map to the claim terms (carrier broadly defined).
What method-of-use claims protect: VHL disease and renal cell carcinoma (including clear cell)?
Indication map
- VHL disease method:
- Claim 18: method treating VHL disease using the composition of claim 15 (thus anchored to claim 1 chemistry).
- RCC methods:
- Claim 22: method treating renal cell carcinoma using the composition of claim 15 (claim 1 chemistry).
- Further method paths anchored to claim 5 and claim 14:
- Claim 23-25: VHL and RCC methods anchored to the compound of claim 5.
- Claim 26-28: VHL and RCC methods anchored to the compound of claim 14.
Subpopulation claim: hemangioblastoma, pheochromocytoma, pancreatic NET, renal cell carcinoma
- Claim 19: claim 18 subject also suffers from hemangioblastoma, pheochromocytoma, pancreatic neuroendocrine tumor, or renal cell carcinoma.
- Claim 24: similar refinement for claim 23.
- Claim 27: similar refinement for claim 26.
Explicit clear cell RCC
- Claim 20: claim 19 subject suffers from renal cell carcinoma.
- Claim 21: claim 20 further limits to clear cell renal cell carcinoma.
Infringement consequence:
- A drug approved specifically for clear cell RCC (and prescribed for that indication) is directly aligned with claims 20-21 when anchored to claim 15.
- Even if the active maps to claim 14, claims 26-28 can still capture method-of-use for VHL and RCC without needing claim 15 chemistry.
Claim structure redundancy
The same therapeutic idea appears three times (anchored to claim 15, claim 5, and claim 14). This reduces the risk that a design-around on one scaffold family avoids all use coverage.
How strong is the patent estate within this patent: claim stacking and enforcement leverage?
High-leverage features
- Multiple chemical tiers: Formula I (claim 1), Formula III (claim 5), and a specific enantiomer (claim 14).
- Composition claims: claims 15-17.
- Method claims for core indications: VHL disease and renal cell carcinoma, including clear cell RCC as explicit.
- Stereochemistry and ee: claim 12 adds enforcement against specific optical purity.
Main “design-around” pressure points
- Not all stereoisomers: If an accused product is a different enantiomer, claim 14 may not read. Claim 5 likely still reads if it covers the same stereochemical form, but claim 12’s ee threshold can matter.
- R4 motif switching: The R4 selection and the R3=H proviso can force an alternative sulfoximine/sulfonamide chemistry that may fall outside the formula boundaries.
- R1 substitution strategy: Claim 1 allows broad monocyclic aryl/heteroaryl selection, but the specific selection group and claims 2/3/13 limit to phenyl/pyridyl with substitution patterns.
What does this mean for generic or biosimilar risk scenarios (chemical small molecule, not biologic)?
This is a small-molecule chemical patent with formulation and use claims. It creates three distinct infringement pathways:
- Direct product infringement (making/selling a compound within claims 1/5/14).
- Composition infringement if a generic markets a formulation containing an infringing compound.
- Method-of-use infringement if the product is administered for VHL disease or RCC (and the patient population matches the claim refinements where they are required by dependent claims).
Because the claim set is not limited to a specific dosage form beyond “pharmaceutically acceptable carrier,” formulation changes do not avoid claim 15-17 if the active ingredient is within the chemical scope.
What is the likely regulatory strategy impact: Orange Book listing and Paragraph IV exposure?
For a U.S. small molecule, the practical enforcement route is typically:
- Patent-listed in the FDA Orange Book under the listed NDA/ANDA.
- If a generic files an ANDA with Paragraph IV certification, it must address the listed patents.
- This claim set is tailored to provide coverage across (i) active ingredient, (ii) compositions, and (iii) method-of-use, increasing the probability that an ANDA filer must address multiple listed patents or multiple use codes.
However, no Orange Book numbers, NDA/ANDA identifiers, listed patents, or jurisdictional litigation details were provided with your prompt. Without those, a precise Orange Book mapping cannot be produced here.
How to read claim scope for infringement: “Formula” claims and element-by-element matching
Chemical infringement (claims 1 and 5)
An accused compound must satisfy:
- Scaffold features corresponding to Formula I/III core.
- R1 is within the monocyclic aryl/heteroaryl selection and, per the claim text, consistent with the internal R1 selection group.
- R2 and R3 meet the specified functional options and the special ring-forming option.
- R4 meets the enumerated set, and the R3=H proviso imposes a specific S(=O)(=N…) substituted motif.
Stereochemical infringement (claim 14 and ee in claim 12)
- Claim 14 targets a specific (S) enantiomer with defined connectivity and substituents.
- Claim 12 targets ≥ about 85% ee for the claim 5 compound.
Use infringement (claims 18-28)
- Independent method claims: 18 and 22 (anchored to claim 15 chemistry), 23 and 25 (anchored to claim 5 chemistry), 26 and 28 (anchored to claim 14 chemistry).
- Dependent method claims add patient-type qualifiers and, in 20-21, clear cell RCC.
Patent landscape: how this patent usually sits in a “family” and what adjacent patents typically cover
No other patent numbers, assignees, priority filings, continuation links, prosecution history, or litigation docket were provided in the prompt. Without those identifiers, a complete landscape across related U.S. family members (continuations, divisionals, salt polymorphs, dosage forms, manufacturing processes, and combination therapies) cannot be produced accurately.
What can be concluded from the claim architecture alone:
- This patent likely corresponds to one or more chemical matter + stereochemical + use layers commonly issued across a granted family.
- The dependent patient-indication language suggests the assignee also pursued therapeutic method claims tied to clinical development.
Key takeaways
- U.S. 9,908,845 is a layered protection package: chemical matter (Formula I/III + specific (S) compound), compositions (claims 15-17), and therapeutic methods (VHL disease and renal cell carcinoma, including clear cell RCC in claims 20-21).
- The most enforcement-relevant chemical coverage is anchored by claim 14 plus broader Formula claims (1 and 5).
- Claim 12’s ≥85% enantiomeric excess can constrain infringement for optical purity and stereochemical manufacturing routes.
- The claim set is structured to reduce easy design-around through redundancy: the same indications are claimed three times (anchored to claim 1, claim 5, and claim 14).
FAQs
-
Can a generic avoid infringement by changing the pharmaceutically acceptable carrier in claims 15-17?
No, the carrier is broad; the key is whether the generic contains an infringing compound within claims 1/5/14.
-
What role does claim 12’s “≥ about 85% enantiomeric excess” play in infringement risk?
It can matter if an accused product is within the claim 5 structural scope but made and sold with lower enantiomeric excess.
-
Does clear cell renal cell carcinoma have a standalone method claim?
It is explicitly recited as a dependent limitation through claims 20-21 under the RCC method pathway anchored to claim 15.
-
Is the R4 functional group the main design-around variable?
It is a major constraint because R4 is enumerated and, when R3=H, is further restricted to a specific S(=O)(=N…) structure with fluoroalkyl substitution.
-
Do the method claims require a particular dosage or regimen?
The claims as provided are indication-based (“administering an effective amount”) and do not add explicit dosing schedules in the claim text shown.
References (APA)
- United States Patent 9,908,845. (n.d.). [Claims excerpt provided by user].
More… ↓
⤷ Start Trial
|
